Sugi Predict

Sugi Predict / Compounds / SCHEMBL188299

SCHEMBL188299

SCHEMBL188299

COc1c[c]ccc1OCCCN(C)C

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 1/20 0.44
▸ HTR1B P28222 2/20 0.43
▸ HRH3 Q9Y5N1 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ HRH1 P35367 1/20 0.41
▸ BCHE P06276 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ THRA P10827 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ LSS P48449 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL188489 0.94 HTR7 (0.44) HTR7HTR1BHRH3CYP1A2CYP2D6
SCHEMBL2479633 0.92 HTR7 (0.53) HTR7HTR1BHRH3ALDH1A1KDM4E
SCHEMBL4577229 0.85 HTR7 (0.53) HTR7HTR1BHRH3ALDH1A1KDM4E
SCHEMBL3514601 0.84 ALDH1A1 (0.57) ALDH1A1KDM4EBCHEACHE
SCHEMBL188652 0.83 CYP1A2 (0.47) HTR1BHRH3CYP1A2CYP2D6CYP2C19
SCHEMBL460078 0.81 L3MBTL1 (0.39) CYP1A2CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL7180376 0.81 CYP1A2 (0.41) CYP1A2CYP2C19ALDH1A1SMN1; SMN2THRA
SCHEMBL27869504 0.81 ALDH1A1 (0.44) HTR1BHRH3CYP1A2CYP2D6CYP2C19
SCHEMBL6017158 0.81 KDM4E (0.48) HTR1BHRH3CYP1A2CYP2D6CYP2C19
SCHEMBL27639452 0.81 HTR1B (0.43) HTR1BHRH3CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373169-B1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT INC (US) 2015-05-20 — — EP claimed
US-20140336169-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2014-11-13 — — US claimed
US-8748607-B2 Imidazopyrizine syk inhibitors GILEAD CONNECTICUT, INC. (US) 2014-06-10 — — US claimed
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-12 — — US claimed
US-20130237521-A1 IMIDAZOPYRIZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-12 — — US claimed
US-8455493-B2 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2013-06-04 — — US claimed
EP-2373169-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2011-10-12 — — EP claimed
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-09-02 — — US claimed
WO-2010068257-A1 IMIDAZOPYRAZINE SYK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-06-17 — — WO claimed
US-20180086769-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2018-03-29 — — US disclosed
US-9796718-B2 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine GILEAD CONNECTICUT, INC. (US) 2017-10-24 — — US disclosed
EP-3123864-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2017-02-01 — — EP disclosed
EP-2716157-B1 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT INC (US) 2016-05-18 — — EP disclosed
US-20160031894-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2016-02-04 — — US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 — — US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 — — EP disclosed
EP-2373169-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2011-10-12 — — EP disclosed
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-09-02 — — US disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 — — WO disclosed
WO-2010068257-A1 IMIDAZOPYRAZINE SYK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031894-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 HTR7 2603/4885HTR1B 4059/4885HRH3 1483/4885
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 HTR7 2603/4885HTR1B 4059/4885HRH3 1483/4885
US-20180086769-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 HTR7 2603/4885HTR1B 4059/4885HRH3 1483/4885
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK HTR7 4068/4885HTR1B 3132/4885HRH3 1505/4885
US-20140336169-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 HTR7 2603/4885HTR1B 4059/4885HRH3 1483/4885
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 HTR7 2603/4885HTR1B 4059/4885HRH3 1483/4885
US-20130237521-A1 IMIDAZOPYRIZINE SYK INHIBITORS SYK, ZAP70, BTK HTR7 2943/4885HTR1B 4220/4885HRH3 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.